{
    "2020-01-21": [
        [
            {
                "time": "2020-01-23",
                "original_text": "智飞生物针对武汉冠状肺炎病毒的相关药品和疫苗的回答",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "武汉",
                        "冠状肺炎",
                        "药品",
                        "疫苗"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-23",
                "original_text": "智飞生物：在研产品暂未涉及武汉2019新型冠状病毒",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "在研产品",
                        "武汉",
                        "2019新型冠状病毒"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}